Wang, Ying

Basic Info

Academic Rank:

Assistant Professor, Department of Pathology and Laboratory Medicine


Centre for Heart Lung


St. Paul’s Hospital

Short Bio

Dr. Wang is a Michael Smith Health Research BC Scholar and a Heart and Stroke Foundation of Canada New Investigator at Centre for Heart Lung Innovation, St. Paul’s Hospital. She received her Ph.D. in Pharmaceutical Sciences from University of British Columbia. During her postdoc training at UBC and Stanford University, she received several prestigious international awards, including the Elaine W. Raines Early Career Investigator Award by the American Heart Association and the Junior Investigator Award by Fondation Leducq PlaqOmics Trans-Atlantic Consortium. Her research program integrates cutting-edge ‘Omics’ technologies, biobank resources, and mechanistic studies to improve treatment outcomes of ischemic heart disease. Upon joining UBC in 2021, she attracted >1.8 million research funding as the principal investigator. In 2002, Dr. Wang was appointed as the Director of Bruce McManus Cardiovascular Biobank, which has the largest collection of explanted hearts in Canada.


Academic Background


  • Post-doctoral fellow, Department of Vascular Surgery, Stanford University, Stanford, US.
  • Post-doctoral fellow, Department of Medicine, University of British Columbia, Vancouver.
  • PhD, Pharmaceutical Sciences, University of British Columbia.

Awards & Recognition

2022-2027: Michael Smith Health Research BC Scholar

2022-2025: Heart and Stroke Foundation of Canada New Investigator

2023: Stewart Whitman New Investigator Award,Canadian Society of Atherosclerosis, Thrombosis and Vascular Biology & Canadian Lipoprotein and Vascular Summit

2023: Department of Pathology and Laboratory Medicine Research and Discovery Award

2021: UBC Faculty of Medicine New Faculty Research Award

Selected Publications

For a list of Dr. Wang’s publications, click


Current Openings & Opportunities

Current Projects In My Lab include

1. Finding therapeutic targets to remove diseased cells in the atherosclerotic lesions.

2. Drug repurposing for atherosclerotic disease

3. Developing spatial and single-cell endotyping technologies for cardiovascular tissues


Dr. Wang’s research aims to advance cardiovascular medicine for patients who suffer from ischemic heart disease. Therapeutics, vascular biology, and technology development are the three pillars of the research program.
Atherosclerosis: therapeutic target mapping, biomarkers, pharmacology
Vascular biology: vascular smooth muscle cells, cell-cell/microenvironment interaction
Endotyping technology: multiplex imaging, spatial gene expression, disease modeling